The path to profits for most of Corporate America lately has been cutting costs rather than raising revenue. But a careful look reveals a few companies that are poised to deliver real revenue growth. We’ve found six with a plus…
From Jan. 10 to 13, thousands of investment pros and corporate chiefs flocked to the St. Francis Hotel for standing-room-only annual health care conference hosted by JPMorgan Chase. But two other, smaller but just as interestin…
If you’ve been to a supermarket lately, you’ve probably noticed that food prices are soaring. And that spells an opportunity for investors. Asset-management expert John Stephenson offers tips for small investors aiming to tap i…
This little-known biopharmaceutical outfit has signed not just one but seven partnership pacts with Big Pharmas to help develop some of its products. Micromet’s No. 1 appeal: It’s developing novel antibody-based drugs to treat …
The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a b…